These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
549 related articles for article (PubMed ID: 27392648)
41. Engineering chimeric antigen receptor-T cells for cancer treatment. Ye B; Stary CM; Li X; Gao Q; Kang C; Xiong X Mol Cancer; 2018 Feb; 17(1):32. PubMed ID: 29448937 [TBL] [Abstract][Full Text] [Related]
42. Challenges and prospects of chimeric antigen receptor T cell therapy in solid tumors. Jindal V; Arora E; Gupta S Med Oncol; 2018 May; 35(6):87. PubMed ID: 29730801 [TBL] [Abstract][Full Text] [Related]
43. [T cell-based immunotherapies in solid tumors]. Baulu E; Dougé A; Chuvin N; Bay JO; Depil S Bull Cancer; 2021 Oct; 108(10S):S96-S108. PubMed ID: 34920813 [TBL] [Abstract][Full Text] [Related]
44. Chimeric Antigen Receptor T Cell Based Immunotherapy for Cancer. Li F; Zhang T; Cao L; Zhang Y Curr Stem Cell Res Ther; 2018; 13(5):327-335. PubMed ID: 29676233 [TBL] [Abstract][Full Text] [Related]
46. Role of gammadelta T lymphocytes in tumor defense. Zocchi MR; Poggi A Front Biosci; 2004 Sep; 9():2588-604. PubMed ID: 15358583 [TBL] [Abstract][Full Text] [Related]
47. Establishing guidelines for CAR-T cells: challenges and considerations. Wang W; Qin DY; Zhang BL; Wei W; Wang YS; Wei YQ Sci China Life Sci; 2016 Apr; 59(4):333-9. PubMed ID: 26965523 [TBL] [Abstract][Full Text] [Related]
48. Genetic engineering of T cells with chimeric antigen receptors for hematological malignancy immunotherapy. Ti D; Niu Y; Wu Z; Fu X; Han W Sci China Life Sci; 2018 Nov; 61(11):1320-1332. PubMed ID: 30414005 [TBL] [Abstract][Full Text] [Related]
49. Engineering CAR-T Cells for Improved Function Against Solid Tumors. Morgan MA; Schambach A Front Immunol; 2018; 9():2493. PubMed ID: 30420856 [TBL] [Abstract][Full Text] [Related]
50. Adoptive T cell therapy: points to consider. Yee C Curr Opin Immunol; 2018 Apr; 51():197-203. PubMed ID: 29730057 [TBL] [Abstract][Full Text] [Related]
51. Bispecific T-cells expressing polyclonal repertoire of endogenous γδ T-cell receptors and introduced CD19-specific chimeric antigen receptor. Deniger DC; Switzer K; Mi T; Maiti S; Hurton L; Singh H; Huls H; Olivares S; Lee DA; Champlin RE; Cooper LJ Mol Ther; 2013 Mar; 21(3):638-47. PubMed ID: 23295945 [TBL] [Abstract][Full Text] [Related]
52. Alphabeta T-cell receptor engineered gammadelta T cells mediate effective antileukemic reactivity. van der Veken LT; Hagedoorn RS; van Loenen MM; Willemze R; Falkenburg JH; Heemskerk MH Cancer Res; 2006 Mar; 66(6):3331-7. PubMed ID: 16540688 [TBL] [Abstract][Full Text] [Related]
53. Principles of adoptive T cell therapy in cancer. Met Ö; Jensen KM; Chamberlain CA; Donia M; Svane IM Semin Immunopathol; 2019 Jan; 41(1):49-58. PubMed ID: 30187086 [TBL] [Abstract][Full Text] [Related]
54. Engineering for Success: Approaches to Improve Chimeric Antigen Receptor T Cell Therapy for Solid Tumors. Mata M; Gottschalk S Drugs; 2019 Mar; 79(4):401-415. PubMed ID: 30796733 [TBL] [Abstract][Full Text] [Related]
56. Adoptive T cell therapy: Boosting the immune system to fight cancer. Leon E; Ranganathan R; Savoldo B Semin Immunol; 2020 Jun; 49():101437. PubMed ID: 33262066 [TBL] [Abstract][Full Text] [Related]
57. Chimeric antigen-receptor T-cell therapy for hematological malignancies and solid tumors: Clinical data to date, current limitations and perspectives. Gauthier J; Yakoub-Agha I Curr Res Transl Med; 2017 Sep; 65(3):93-102. PubMed ID: 28988742 [TBL] [Abstract][Full Text] [Related]
58. Engineering γδT cells limits tonic signaling associated with chimeric antigen receptors. Fisher J; Sharma R; Don DW; Barisa M; Hurtado MO; Abramowski P; Porter L; Day W; Borea R; Inglott S; Anderson J; Pe'er D Sci Signal; 2019 Sep; 12(598):. PubMed ID: 31506382 [TBL] [Abstract][Full Text] [Related]
59. Regional Infusion of Chimeric Antigen Receptor T Cells to Overcome Barriers for Solid Tumor Immunotherapy. Hardaway JC; Prince E; Arepally A; Katz SC J Vasc Interv Radiol; 2018 Jul; 29(7):1017-1021.e1. PubMed ID: 29935783 [No Abstract] [Full Text] [Related]